Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Docetaxel and Thalidomide as a Second-Line Treatment for Non-Small Cell Lung Cancer

NCT00114192 is registered in ClinicalTrials.gov with University of Virginia as lead sponsor.

NCT NCT00114192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00114192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Docetaxel and Thalidomide as a Second-Line Treatment for Non-Small Cell Lung Cancer
Lead sponsor
University of Virginia
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2004
Completion date
Not reported
Enrollment
37 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer